{"id":23832,"date":"2025-05-15T13:30:39","date_gmt":"2025-05-15T06:30:39","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23832"},"modified":"2025-05-15T13:30:39","modified_gmt":"2025-05-15T06:30:39","slug":"2025-asgct-immunofocos-in-vivo-car-t-technology-platform-debuts-with-groundbreaking-innovations","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23832","title":{"rendered":"2025 ASGCT | Immunofoco&#8217;s In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations"},"content":{"rendered":"<ul type=\"disc\">\n<li><i>MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency.<\/i><\/li>\n<li><i>The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity.<\/i><\/li>\n<li><i>With various TCMs, the MxV-G mutant selectively transduced T cells, yielding CAR-T cells in mice with efficiency and anti-tumor efficacy comparable to wild-type.<\/i><\/li>\n<li><i>TCM3, our in-house developed T cell\u2013targeting module, is designed for specific binding, activation, and transduction of T cells.<\/i><\/li>\n<li><i>TCM3 achieved higher T cell transduction rates than \u03b1CD3\/CD80\/CD58 and \u03b1CD3\/CD80 across various fusogen mutants.<\/i><\/li>\n<li><i>MxV-G-mut+TCM3 exhibited superior specificity profile on a panel of human normal or malignant cells<\/i><\/li>\n<li><i>TCM3 demonstrated more potent anti-tumor efficacy in mice model.<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In Vivo CAR-T Technology Platform made a remarkable appearance at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). This platform has broken the patent barriers in this field, achieving significant in-vitro and in-vivo specificity and efficacy, and providing a new strategy for tumor immunotherapy.<\/p>\n<p><b>Novel Lentiviral Vector: Overcoming Patent Barriers with Superior Performance<\/b><\/p>\n<p>Immunofoco&#8217;s team developed a novel lentiviral vector pseudotyped with the MxV glycoprotein (MxV-G), demonstrating performance in generating CAR-T cells in vivo. Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more effectively target and kill tumor cells. This novel envelope has good clinical application potential in both traditional ex vivo CAR-T and in vivo CAR-T.<\/p>\n<p><b>AI-Driven Optimization: Successful Construction of Precision-Engineered Tropism-Modified Mutants<\/b><\/p>\n<p>To eliminate the natural tropism of MxV-G and enhance its specificity, the team used an AI-driven protein model to successfully design and construct a mutant MxV-G. The mutated MxV-G eliminates the infectivity to non-T cells while retaining its membrane-fusion-mediating activity. By introducing different T-cell targeting modules, its infectivity to T cells is restored, achieving precise targeting and improving the safety and efficacy of treatment.<\/p>\n<p><b>Next-Generation T-Cell Targeting Molecules: Upgrading Specificity and Anti-Tumor Activity<\/b><\/p>\n<p>To target T cells precisely, the team engineered multiple T-cell-targeting molecules (TCM). TCM3 demonstrated selective T-cell transduction with no off-target effects and outperformed \u03b1CD3\/CD80\/CD58 (MDF) and \u03b1CD3\/CD80 in efficiency when paired with different membrane fusion protein variants. CAR-T cells generated by MxV-G-TCM3 showed high specificity across cell lines and reduced T-cell exhaustion markers, supporting sustained activity and improved tumor control. In mouse models, this combination exhibited significantly stronger in vivo anti-tumor efficacy compared to \u03b1CD3\/CD80\/CD58.<\/p>\n<p>Dr. Hao Ruidong, Partner and Head of the R &amp; D Center at Immunofoco, said, &#8220;CAR-T cell therapy has revolutionized cancer treatment, yet its complex manufacturing and high costs limit accessibility. Our novel in vivo CAR-T platform, powered by lentiviral technology, breaks foreign patent barriers in fusion proteins and T-cell targeting while showing strong in-vitro and in-vivo specificity and efficacy. With simpler manufacturing and lower costs, we aim to make this life-saving treatment accessible to more patients. Moving forward, we&#8217;ll advance its clinical potential to maximize impact.&#8221;<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li><i>MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency.<\/i><\/li>\n<li><i>The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity.<\/i><\/li>\n<li><i>With various TCMs, the MxV-G mutant selectively transduced T cells, yielding CAR-T cells in mice with efficiency and anti-tumor efficacy comparable to wild-type.<\/i><\/li>\n<li><i>TCM3, our in-house developed T cell\u2013targeting module, is designed for specific binding, activation, and transduction of T cells.<\/i><\/li>\n<li><i>TCM3 achieved higher T cell transduction rates than \u03b1CD3\/CD80\/CD58 and \u03b1CD3\/CD80 across various fusogen mutants.<\/i><\/li>\n<li><i>MxV-G-mut+TCM3 exhibited superior specificity profile on a panel of human normal or malignant cells<\/i><\/li>\n<li><i>TCM3 demonstrated more potent anti-tumor efficacy in mice model.<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In Vivo CAR-T Technology Platform made a remarkable appearance at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). This platform has broken the patent barriers in this field, achieving significant in-vitro and in-vivo specificity and efficacy, and providing a new strategy for tumor immunotherapy.<\/p>\n<p><b>Novel Lentiviral Vector: Overcoming Patent Barriers with Superior Performance<\/b><\/p>\n<p>Immunofoco&#8217;s team developed a novel lentiviral vector pseudotyped with the MxV glycoprotein (MxV-G), demonstrating performance in generating CAR-T cells in vivo. Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more effectively target and kill tumor cells. This novel envelope has good clinical application potential in both traditional ex vivo CAR-T and in vivo CAR-T.<\/p>\n<p><b>AI-Driven Optimization: Successful Construction of Precision-Engineered Tropism-Modified Mutants<\/b><\/p>\n<p>To eliminate the natural tropism of MxV-G and enhance its specificity, the team used an AI-driven protein model to successfully design and construct a mutant MxV-G. The mutated MxV-G eliminates the infectivity to non-T cells while retaining its membrane-fusion-mediating activity. By introducing different T-cell targeting modules, its infectivity to T cells is restored, achieving precise targeting and improving the safety and efficacy of treatment.<\/p>\n<p><b>Next-Generation T-Cell Targeting Molecules: Upgrading Specificity and Anti-Tumor Activity<\/b><\/p>\n<p>To target T cells precisely, the team engineered multiple T-cell-targeting molecules (TCM). TCM3 demonstrated selective T-cell transduction with no off-target effects and outperformed \u03b1CD3\/CD80\/CD58 (MDF) and \u03b1CD3\/CD80 in efficiency when paired with different membrane fusion protein variants. CAR-T cells generated by MxV-G-TCM3 showed high specificity across cell lines and reduced T-cell exhaustion markers, supporting sustained activity and improved tumor control. In mouse models, this combination exhibited significantly stronger in vivo anti-tumor efficacy compared to \u03b1CD3\/CD80\/CD58.<\/p>\n<p>Dr. Hao Ruidong, Partner and Head of the R &amp; D Center at Immunofoco, said, &#8220;CAR-T cell therapy has revolutionized cancer treatment, yet its complex manufacturing and high costs limit accessibility. Our novel in vivo CAR-T platform, powered by lentiviral technology, breaks foreign patent barriers in fusion proteins and T-cell targeting while showing strong in-vitro and in-vivo specificity and efficacy. With simpler manufacturing and lower costs, we aim to make this life-saving treatment accessible to more patients. Moving forward, we&#8217;ll advance its clinical potential to maximize impact.&#8221;<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23832"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23832\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}